Is DWTX or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -63.38% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Kiora Pharmaceuticals N/A -63.38% -44.33%

Do analysts prefer PYRGF or KPRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate FLNA or KPRX?

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 437.11%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FLNA or KPRX more profitable?

Cassava Sciences' return on equity of -58.78% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Kiora Pharmaceuticals N/A -63.38% -44.33%

Do analysts rate GRCE or KPRX?

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 189.86%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRCE or KPRX more profitable?

Grace Therapeutics' return on equity of -36.11% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Kiora Pharmaceuticals N/A -63.38% -44.33%

Do analysts recommend VERU or KPRX?

Veru presently has a consensus target price of $24.50, indicating a potential upside of 876.10%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VERU or KPRX more profitable?

Veru's return on equity of -47.58% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Kiora Pharmaceuticals N/A -63.38% -44.33%

Kiora Pharmaceuticals (KPRX) Competitors

$2.56 -0.02 (-0.78%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.56 0.00 (-0.20%)

As of 10/2/2026 04:10 PM Eastern

Compare

KPRX vs. DWTX, PYRGF, FLNA, GRCE, and VERU

Should you buy Kiora Pharmaceuticals stock or one of its competitors? Kiora Pharmaceuticals's main competitors and comparable companies include Dogwood Therapeutics (DWTX), PyroGenesis Canada (PYRGF), Cassava Sciences (FLNA), Grace Therapeutics (GRCE), and Veru (VERU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Kiora Pharmaceuticals compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Dogwood Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -63.38% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Kiora Pharmaceuticals has higher revenue and earnings than Dogwood Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.51	N/A

In the previous week, Dogwood Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Kiora Pharmaceuticals	Neutral

Dogwood Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 721.92%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Dogwood Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Dogwood Therapeutics and Kiora Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

PyroGenesis Canada has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

Kiora Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kiora Pharmaceuticals has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.53	-$21.12M	-$0.04	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.51	N/A

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, PyroGenesis Canada had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for PyroGenesis Canada and 0 mentions for Kiora Pharmaceuticals. PyroGenesis Canada's average media sentiment score of 0.22 beat Kiora Pharmaceuticals' score of 0.00 indicating that PyroGenesis Canada is being referred to more favorably in the media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Kiora Pharmaceuticals	Neutral

Summary

PyroGenesis Canada and Kiora Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Kiora Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.51	N/A

Cassava Sciences has a beta of -0.65, suggesting that its share price is 165% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market.

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cassava Sciences had 8 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 8 mentions for Cassava Sciences and 0 mentions for Kiora Pharmaceuticals. Cassava Sciences' average media sentiment score of 1.23 beat Kiora Pharmaceuticals' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
Kiora Pharmaceuticals	Neutral

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 437.11%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cassava Sciences' return on equity of -58.78% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Summary

Cassava Sciences beats Kiora Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Grace Therapeutics' return on equity of -36.11% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 189.86%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Grace Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market.

In the previous week, Grace Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Kiora Pharmaceuticals. Grace Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Grace Therapeutics	Neutral
Kiora Pharmaceuticals	Neutral

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.51	N/A

Summary

Grace Therapeutics beats Kiora Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Veru?

Veru (NASDAQ:VERU) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Veru's return on equity of -47.58% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Veru has a beta of -1.21, meaning that its stock price is 221% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market.

Kiora Pharmaceuticals has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	N/A	N/A	-$22.73M	-$0.69	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.51	N/A

In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 beat Veru's score of -0.35 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Neutral
Kiora Pharmaceuticals	Neutral

47.2% of Veru shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Veru presently has a consensus target price of $24.50, indicating a potential upside of 876.10%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Veru beats Kiora Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.33M	$12.28B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-1.02	802.26	274.71	26.04
Price / Sales	0.71	940.01	656.46	105.13
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	0.58	10.52	10.93	6.31
Net Income	-$10.84M	$2.86B	$3.51B	$362.16M
7 Day Performance	-2.66%	-1.58%	-2.00%	-1.66%
1 Month Performance	0.39%	-5.55%	-6.19%	-4.68%
1 Year Performance	-6.91%	-2.19%	8.03%	1.57%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	0.3633 of 5 stars	$2.56 -0.8%	N/A	-6.9%	$11.33M	$16.02M	N/A	13
DWTX Dogwood Therapeutics	3.1665 of 5 stars	$1.35 flat	$12.00 +788.9%	-77.2%	$45.89M	N/A	N/A	8
PYRGF PyroGenesis Canada	N/A	$0.20 +20.7%	N/A	+9.1%	$45.52M	$9.14M	N/A	90	News Coverage
FLNA Cassava Sciences	2.9465 of 5 stars	$0.89 -4.2%	$5.00 +464.3%	-74.4%	$44.67M	N/A	N/A	30	News Coverage Positive News Insider Trade
GRCE Grace Therapeutics	1.9944 of 5 stars	$2.15 +1.9%	$6.00 +179.1%	-31.7%	$44.39M	N/A	N/A	5	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. DWTX, PYRGF, FLNA, GRCE, and VERU

How does Kiora Pharmaceuticals compare to Dogwood Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to PyroGenesis Canada?

Summary

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Summary

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Veru?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. DWTX, PYRGF, FLNA, GRCE, and VERU

How does Kiora Pharmaceuticals compare to Dogwood Therapeutics?

Which has more risk and volatility, DWTX or KPRX?

Is DWTX or KPRX more profitable?

Which has preferable earnings and valuation, DWTX or KPRX?

Does the media favor DWTX or KPRX?

Do analysts prefer DWTX or KPRX?

Do insiders and institutionals hold more shares of DWTX or KPRX?

Summary

How does Kiora Pharmaceuticals compare to PyroGenesis Canada?

Which has more risk & volatility, PYRGF or KPRX?

Is PYRGF or KPRX more profitable?

Do analysts prefer PYRGF or KPRX?

Which has better valuation & earnings, PYRGF or KPRX?

Do institutionals and insiders have more ownership in PYRGF or KPRX?

Does the media favor PYRGF or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Which has higher earnings and valuation, FLNA or KPRX?

Which has more volatility & risk, FLNA or KPRX?

Do insiders and institutionals have more ownership in FLNA or KPRX?

Does the media favor FLNA or KPRX?

Do analysts rate FLNA or KPRX?

Is FLNA or KPRX more profitable?

Summary

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Is GRCE or KPRX more profitable?

Do analysts rate GRCE or KPRX?

Which has more volatility and risk, GRCE or KPRX?

Does the media refer more to GRCE or KPRX?

Do insiders & institutionals have more ownership in GRCE or KPRX?

Which has preferable earnings & valuation, GRCE or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Veru?

Is VERU or KPRX more profitable?

Which has more risk and volatility, VERU or KPRX?

Which has stronger earnings and valuation, VERU or KPRX?

Does the media favor VERU or KPRX?

Do institutionals and insiders have more ownership in VERU or KPRX?

Do analysts recommend VERU or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools